|Bid||1.6900 x 900|
|Ask||1.7000 x 900|
|Day's Range||1.6500 - 1.8200|
|52 Week Range||1.5300 - 10.7000|
|Beta (5Y Monthly)||0.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 01, 2022 - Feb 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
Subscribe to Yahoo Finance Plus to view Fair Value for LCILearn more
Lannett (LCI) delivered earnings and revenue surprises of -8.00% and 2.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Good afternoon, everyone, and thank you for joining us today to discuss Lannett Company's fiscal 2022 first quarter financial results. On the call today are Tim Crew, Chief Executive Officer; John Kozlowski, the company's Chief Financial Officer; Maureen Cavanaugh, our Chief Commercial Operations Officer; and Steve Lehrer, who leads our biosimilar insulin initiatives.
Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2022 first quarter ended September 30, 2021.